在患有初级高血压的患者中,甘油三糖指数和高尿血之间的关联:一个横截面研究
Shanshan Liu1, Zhixian Zhou2, Miao Wu2
1Department of Cardiology, Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine, Nanchang, Jiangxi, China.
International journal of endocrinology
|June 26, 2023
概括
三甘油糖 (TyG) 指数与高血压患者的高尿血 (HUA) 有积极的关联. 这种联系在患有1-2级高血压的人群中比3级高血压更为强烈.
科学领域:
- 心血管医学 心血管医学
- 代谢综合征研究 代谢综合征研究
- 腎臟病學 (nephrology) 是一種醫學專業.
背景情况:
- 高血压是一个全球性的健康问题.
- 高尿路血 (HUA) 与心血管疾病和功能障碍有关.
- 三甘油糖 (TyG) 指数正在成为胰岛素抵抗和代谢功能障碍的标志物.
研究的目的:
- 在1-3级高血压患者中研究TyG指数和HUA之间的关联.
- 根据高血压的严重程度来探索这种关联中的潜在差异.
主要方法:
- 一项对1707名高血压患者的横截面研究.
- 使用Ln (三糖 × 禁食葡萄糖/2) 计算TyG指数.
- HUA的定义是尿酸≥420μmol/L.
- 采用了多变量逻辑回归,处罚线回归和通用添加模型.
- 对不同级别的高血压进行了分层分析.
主要成果:
- 在对共变量进行调整后,TyG指数和HUA (OR = 1.83;95% CI: 1.40-2.39) 之间发现了正相关性.
- 在TyG指数范围内,相关性是线性的.
- 这种联系在患有1-2级高血压 (OR = 2.22;95% CI: 1.44-3.42) 的患者中比患有3级高血压 (OR = 1.58;95% CI: 1.11-2.24) 的患者更为强烈.
结论:
- 在高血压患者中,TyG指数与HUA正相关.
- 这种关联在不太严重的高血压 (1至2级) 患者中更为明显.
- 研究结果表明,TyG指数可能成为高血压患者中HUA风险的潜在指标.
相关概念视频
Hypertension III: Clinical Manifestations and Diagnostic Studies
33
Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
33
Oral Hypoglycemic Agents: Biguanides and Glitazones
240
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
240
Hypertension II: Pathophysiology
22
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
22
Hypertension I: Introduction
24
Hypertension is a widespread, long-term medical condition where blood pressure in the arteries remains elevated. It is characterized by systolic blood pressure readings of 130 mm Hg or above or diastolic blood pressure (DBP) readings of 80 mm Hg or higher. Unmanaged hypertension poses significant health risks, making the distinction between primary (or essential) hypertension and secondary hypertension crucial, as their management and implications vary.Primary HypertensionPrimary hypertension,...
24
Hypertension and Regulation of Blood Pressure
2.1K
Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
2.1K
Hypoglycemia and Glucagon
306
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
306


